



Thromboelastography – Introduction into a trauma service: benefits and evidence

Dr Dan Ellis

FACEM, FCICM, FCEM, FIMC & DRTM (RCSEd), FFICM, FRCS(Eng), MRCP, MRCA, DMCC, GCertCU

Acting Director of Trauma, Royal Adelaide Hospital

Retrieval Consultant, MedSTAR





Objectives

- > What is it...?
- > Do I need it?
- > How do I get it?
- > What else do I need?
- > Prove its easy to interpret.....
 - +/- cases (time..!)



Key points

- > This is not hard:
 - To acquire
 - To use
 - To interpret
- > It does not take a long time
- > It has the potential:
 - To improve trauma care
 - Reduce blood/product use
 - Save money....



Real questions.....?

- > The Thromboelastogram:
- > Is it a standard of care in trauma centres?
- > Should it be an ED test?



The Technology

- > Viscoelastic Haemostatic Assays
- > The technology is not new
- > Based on classical Thromboelastography
- > First described in 1948 by Hartert
- > ROTEM or TEG
 - Same process, different labels, similar consequences
- > Give information on:
 - Clot Formation
 - Clot Strength
 - Clot Lysis



ROTEM or TEG?

- > Don't ask the rep....
- > TEG – American
- > ROTEM – German

- > Bottom line
 - Either will do.


- > We have a ROTEM
 - No conflict of interest



The design is simple

ROTEM[®] Thromboelastometry - technology

How thick & sticky the clot is



Ambulance
Service

South Australia
SA Health

med
STAR
Emergency Medical Retrieval

When to use ROTEM

Active Haemorrhage

- Trauma
- Massive hemorrhage
- Obstetric hemorrhage
- Acquired coagulation disorders
- Cardiac and vascular surgery
- Bleeding patient



When NOT to use ROTEM

- > Monitoring therapeutic effects of antithrombotic Tx
 - antiplatelet agents: clopidogrel, aspirin, prasugrel
 - Direct Oral Anticoagulants (DOAC):
 - Dabigatran, Rivaroxaban, Apixaban
 - ROTEM will detect the presence, but not the anticoagulant dosage effects, of these drugs
- > ROTEM can be used in patients who are actively bleeding and on warfarin or heparin
 - HEPTTEM can evaluate heparin effect
 - ROTEM is NOT for therapeutic monitoring of either warfarin or heparin



Rotational thromboelastometry-guided blood management in major spine surgery

Bhiken I. Naik, MBBCh,^{1,2} Thomas N. Pajewski, MD, PhD,^{1,2} David L. Boggs, MD, PhD,^{1,2} Pamela Clark, MD, JD,³ Abdullah S. Terkawi, MD,¹ Marcel E. Durieux, MD, PhD,^{1,2} Christopher I. Shaffrey, MD,² and Edward

Departments of ¹Anesthesiology, ²Neurosurgery, and ³Pathology, University of Virginia, Charlottesville

CONCLUSIONS In major spine surgery, ROTEM-guided transfusion allows for standardization of transfusion practices and early identification and treatment of hypofibrinogenemia. Hypofibrinogenemia is an important cause of the coagu-

CONCLUSION:

The introduction of ROTEM significantly improved adherence to DCR practices. The transfusion differences suggest that aggressive DCR without thromboelastometry data may result in reduced hemostatic support and underestimate the need for PLT and CRYO. Thus, future controlled trials should include ROTEM-guided coagulation management in trauma resuscitation. (*J Trauma Acute Care Surg.* 2017;83: 373–380. Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.)

Conclusions. The significant reduction in allogeneic blood product requirements during surgical burn wound excision is a prospective proof of concept that a bleeding management algorithm based on thromboelastometry is efficacious. Hypofibrinogenemia

CONCLUSION:

We found strong associations between TEG early amplitudes A5/A10 and maximum amplitude in rapid TEG, kaolin TEG, and TEG functional fibrinogen across trauma patients with coagulopathy and massive transfusion requirements. Introducing the use of early amplitudes can reduce time to diagnosis of coagulopathy and may be used in TEG monitoring of trauma patient. Further randomized controlled trials evaluating the role of TEG in guiding hemostatic resuscitation are warranted. (*J Trauma Acute Care Surg.* 2018;84: 334–341. Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.)

LEVEL OF EVIDENCE: Prognostic study, level III

Thrombelastography early amplitudes in bleeding and coagulopathic trauma patients: Results from a multicenter study

Thomas H. Laursen, MD, Martin A.S. Meyer, MD, Anna Sina P. Meyer, MD, Tina Gaarder, MD, PhD, Paal A. Naess, MD, PhD, Jakob Stensballe, MD, PhD, Sisse R. Ostrowski, MD, PhD, DMSc, and Pär I. Johansson, MD, DMSc, MPA, Copenhagen, Denmark

British Journal of Anaesthesia 109 (3): 376–81 (2012)
Advance Access publication 19 June 2012 · doi:10.1093/bja/aes186

BJA

CRITICAL CARE

treatment algorithm for bleeding burn patients: Allogeneic blood product requirements

E. Schaden¹, O. Kimberger¹, P. Kraincuk¹, D. M. Baron¹, P. G. Metnitz¹ and S. Kozek-Langenecker^{2*}

¹ Department of Anaesthesia, General Intensive Care and Pain Control, Medical University of Vienna, Austria

² Department of Anaesthetics and Intensive Care, Evangelical Hospital Vienna, Austria



Review Article

CPD available at <http://www.learnataagbi.org>

Thromboelastography (TEG) or rotational thromboelastometry (ROTEM) to monitor haemostatic treatment in bleeding patients: a systematic review with meta-analysis and trial sequential analysis

A. Wikkelso,¹ J. Wetterslev,² A. M. Møller³ and A. Afshari⁴

Summary

Coagulopathy and severe bleeding are associated with high mortality. We evaluated haemostatic treatment guided by the functional viscoelastic haemostatic assays, thromboelastography or rotational thromboelastometry in bleeding patients. We searched for randomised, controlled trials irrespective of publication status, publication date, blinding status, outcomes published or language from date of inception to 5 January 2016 in six bibliographic databases. We included 17 trials (1493 participants), most involving cardiac surgery. Thromboelastography or rotational thromboelastometry seemed to reduce overall mortality compared to any of our comparisons (3.9% vs. 7.4%, RR (95%CI) 0.52 (0.28–0.95); $I^2 = 0\%$, 8 trials, 717 participants). However, the quality of evidence is graded as low due to the high risk of bias, heterogeneity, imprecision and low event rate. Thromboelastography or rotational thromboelastometry significantly reduced the proportion of patients transfused with red blood cells (RR (95%CI) 0.86 (0.79–0.94); $I^2 = 0\%$, 10 trials, 832 participants), fresh frozen plasma (RR (95%CI) 0.57 (0.33–0.96); $I^2 = 86\%$, 10 trials, 832 participants) and platelets (RR (95%CI) 0.73 (0.60–0.88); $I^2 = 0\%$, 10 studies, 832 participants). There was no difference in proportion needing surgical re-interventions (RR (95%CI) 0.75 (0.50–1.10); $I^2 = 0\%$, 9 trials, 887 participants). Trial sequential analysis of mortality suggests that only 54% of the required information size has been reached so far. Transfusion strategies guided by thromboelastography

What should we aspire to?

- > Don't necessarily need to give 1:1:1 (or any other ratio)
- > Actually give what you need....
- > Do a ROTEM/TEG and at 5 mins assess that need.....
- > Surely this is best practice....?






Royal Adelaide Hospital blood usage study

- > 2016 - pre
 - > 2017 – intro of ROTEM late in the year
 - > 2018 – post
- > Awaiting the results of 2018 data.....




How do I get it?







Versatile software




ED



ICU



Transfusion



Theatre



- 
- > Not particularly expensive to purchase
 - > Nor to use
 - > Check you don't have access to one already
 - Cardiothoracics
 - Transplant
 - Obstetrics
 - Haematology






> But you need:

- A champion (or more than one....)
- Willingness to adopt
- Multidisciplinary buy in
 - ED
 - Surgery/Anaesthesia/ICU
 - Haematology
- Parallel process (ie use or not use)



Critical Bleeding Algorithm - RAH



Special consideration

- For Warfarin reversal
Vitamin K 5-10 g iv
Prothrombinex – 50 IU/kg
- Platelets for antiplatelet drugs
- Dabigatran reversal
Idarucizumab/Praxbind
- Rivaroban/ Apixaban reversal
Contact critical bleeding specialist

Additional Therapies

- Within 3 hrs of injury
TXA 1g over 10min
Followed by TXA 1g over 8hrs
- Check ionized calcium on blood gas

- ¹ Correctly labelled blood group & hold (G&XM) specimen and form ¹ sent to Transfusion
- ² Haemorrhage starter pack opened and usage form sent to Transfusion via shute
- ³ Check patient's ROTEM via SQ screen – request/use required blood products
- ⁴ Group specific and/or patient named MTP packs and crossmatched units can only be provided with provision of completed Blood Request form (fax or shute)
- ⁵ Contact Critical Bleeding specialist for advice
- ⁶ Regular coagulation tests used


⁴ Blood Product Request form required when issuing Blood Group matched blood

MTP Pack Contents				
	RC	FFP	Plts	Cryo
MTP 1	5	3	1	-
MTP 2	5	4	1	1
MTP 3	5	4	1	1

Interpretation



Hemostasis simplified



Extrinsic pathway

EXTEM

CT:	67s	CFT:	87s	α :	73°
CFR:	54mm	MCF:	57mm	ML:	-%

Intrinsic Pathway

INTEM

CT:	200s	CFT:	67s	α :	77°
CFR:	54mm	MCF:	61mm	ML:	-%

Fibrinogen activity

FIBTEM

CT:	66s	CFT:	-s	α :	57°
CFR:	9mm	MCF:	10mm	ML:	-%

HEPTEM Reverses par...

HEPTEM

CT:	74s	CFT:	89s	α :	72°
CFR:	53mm	MCF:	61mm	ML:	-%

ROTEM Assays

EXTEM Extrinsic pathway screening test

CT not sensitive for heparin (up to 6 U/ml UFH in blood)

CT sensitive for factor deficiency (factor deficiency detected when approximately = <30% factors are left)

Amplitude (A) & CFT influenced by fibrinogen & platelets

INTEM Intrinsic pathway screening test

CT sensitive for heparin (UFH)

CT prolongation from > 0.15 U/ml UFH in blood

CT sensitive for factor deficiency (factor deficiency is only detected when approximately = <30% factors are left)

Amplitude (A) and CFT influenced by fibrinogen & platelets

FIBTEM

identifies isolated fibrinogen contribution to clot firmness

EXTEM activation with platelet inhibition reagent added

Amplitude influenced by fibrinogen concentration & function

APTEM

identifies heparin effect when CT compared with INTEM CT

INTEM activation & heparin inhibition with heparinase

APTEM

confirms presence of hyperfibrinolysis

compare EXTEM ML / LI% with APTEM ML / LI%

EXTEM activation & fibrinolysis inhibition with aprotinin



Rotational Thromboelastometry (ROTEM) A Basic Guide to Clinical Interpretation





www.haemoview.com.au

Key components	
EXTEM CT Clotting Time	Thrombin generation
EXTEM A5 Amplitude at 5 minutes	Fibrinogen and platelet concentration and function
FIBTEM A5 Amplitude at 5 minutes	Fibrinogen concentration and function
ML % Maximal lysis	Degree of fibrinolysis over time


Green = CT
Clotting Time
Initiation
0 – 2 mm

Pink = 2 – 20 mm
Amplification

Blue = A5
Propagation
Fibrin Formation





How it works- Cup and Pin Technology



ROTEM Assays

- EXTEM** Extrinsic pathway screening test
CT not sensitive for heparin (up to 5 U/ml UFH in blood)
CT sensitive for factor deficiency (factor deficiency detected when approximately = <30% factors are left)
Amplitude (A) & CFT influenced by fibrinogen & platelets
- INTEM** Intrinsic pathway screening test
CT sensitive for heparin (UFH)
CT prolongation from > 0.15 U/ml UFH in blood
CT sensitive for factor deficiency (factor deficiency is only detected when approximately = <30% factors are left)
Amplitude (A) and CFT influenced by fibrinogen & platelets
- FIBTEM** Identifies isolated fibrinogen contribution to clot firmness
EXTEM activation with platelet inhibition reagent added
Amplitude influenced by fibrinogen concentration & function
- HEPTEM** Identifies heparin effect when CT compared with INTEM CT
INTEM activation & heparin inhibition with heparinase
- APTEM** Confirms presence of hyperfibrinolysis
compare EXTEM ML / L% with APTEM ML / L%
EXTEM activation & fibrinolysis inhibition with tranexamic acid



Fibrinogen Dosing Guide			
FIBTEM A5 Target: ≥12mm			
FIBTEM A5	Increase required	Cryoprecipitate*	Fibrinogen Concentrate
9-10mm	2-3 mm	10 Units	2g
7-8mm	4-5 mm	15 Units	3g
4-6mm	6-8 mm	20 Units	4g
<4mm	≥8mm	25 Units	5g

*Cryoprecipitate dosing is for standard adult units (Cryo 5 units / Fib Cone 1g = Fibrin A6 increase of approx 2mm)

Always repeat ROTEM 10 mins after treatment



Importance of Clinical Picture


- > **Starting Point**
 - **Bleeding Patient**
 - **High Risk of Bleeding Procedure**
 - **Baseline/Underlying Situation**

- > **‘Link’ ROTEM Diagnostic Findings to Clinical Situation**



The graph information or “TEMogram”

Amplitude
in (mm)




The greater the
amplitude the
firmer the clot

The graph demonstrates the change in amplitude
(clot firmness) over a time period



ROTEM[®] RESULTS


The “TEMograms”



The fatness of the curve is called
“Maximal clot firmness”

or
“MCF”


or
“Amplitude
A5/A10”



5/10 refers to minutes.....



Clot Amplitude = A5/A10/MCF



A5 = amplitude at 5min A10 = amplitude at 10min


MCF = maximum clot firmness These represent the “clot strength”.

Clot firmness = **Clot Quality**

Decreased clot strength is predictive of bleeding




Clotting Time CT



- This represents the time taken for the clot to start forming
- A prolonged clot time can be associated with increased bleeding
- There are a number of potential causes:
 - low fibrinogen
 - low clotting factors (decreased thrombin generation)
 - anticoagulant effect

ROTEM® Parameters



CT (clotting time)
Green display 0-2mm
 Time in seconds from start of measurement until initiation of clotting. Initiation of clotting, thrombin generation and start of clot polymerization

CFT (clot formation time)
Pink display 2-20mm
 Time in seconds from initiation of clotting until a clot firmness of 20 mm is detected. Fibrin polymerisation, stabilisation of the clot with platelets & FXIII.

A10 (amplitude in mm)
Blue display if >20mm
Otherwise stays pink
 Early assessment of clot firmness. Increasing stabilisation of the clot by the polymerised fibrin, platelets as well as FXIII

In a Nutshell – “Time to Treat”

Clotting Time (CT)

- Adequate Clotting Factors
- Inhibited Clotting Factors
- **Amplitude (A5/A10)**
 - Assessment of Clot Strength
 - Fibrinogen / Platelets / FXIII
 - Correlates well with Max Clot Firmness
- **Fibrinolysis**
 - Clot degradation over time
 - Max Lysis (ML)






Emergency department test?

- > Arrival time is T_{ZERO}
 - > Time of first bloods.....
 - > Time to CT.....
 - > Time to theatre/angio....
-
- > When do you plan to give product?
 - > ROTEM is not a once off test



“Normal” ROTEM® TEMograms






Note:

- > Test can be aborted after 5-10 mins if required
- > So you can give product and repeat
- > Or allow another department to do a ROTEM if greater clinical need




In your bleeding patient, ROTEM demonstrates:



A5/10 FIBTEM *Reduced*
A5/10 = 4 mm (>10mm)

**Suggests inadequate
fibrin contribution to clot
firmness: low fibrinogen**


In your bleeding patient, ROTEM demonstrates:



A5/10_{EXTEM} Reduced

Suggests inadequate clot firmness due to either decreased platelets and/or fibrinogen

A5/10 = 27 mm (>40mm)




A5/10_{FIBTEM} Reduced

A5/10 = 4 mm

Suggests inadequate fibrin contribution to clot firmness: low fibrinogen

In your bleeding patient, ROTEM demonstrates:



A5/10_{EX} *Reduced*

Suggests inadequate clot firmness as a result of decreased platelets and/or fibrinogen

A5/10 = 27


A5/10_{FIB} *Normal*

A5/10 = 9mm

Suggests adequate fibrinogen

Platelets are the cause for low A5/10 on EXTEM


In your bleeding patient, ROTEM demonstrates:




ML_{EX} = 30% @ 23MIN

Suggests
hyperfibrinolysis


The APTEM is then run
& lysis is corrected



**Confirms hyperfibrinolysis
and shows efficacy of
antifibrinolytic therapy**



NORMAL ROTEM



RESULTS
 EXTEM CT < 90s
 EXTEM A5 ≥ 40 mm
 FIBTEM A5 ≥ 10 mm
 EXTEM ML < 15 % (30 min)


DIAGNOSIS
 Normal

TREATMENT
 Nil

Note: If ongoing bleeding – repeat ROTEM if no surgical cause found or after initial 4 units of packed red cells

ABNORMAL ROTEMS: (SEE BELOW)

Contact Critical Bleeding Haematologist via switchboard or refer to roster
 Repeat ROTEM 10 min after every intervention to assess response



RESULTS
 FIBTEM A5 ≤ 10 mm

DIAGNOSIS
 Low Fibrinogen


TREATMENT
 Start FFP and give
 1 Adult dose CRYO
 when available



RESULTS
 EXTEM A5 < 40 mm
 AND
 FIBTEM A5 > 10 mm

DIAGNOSIS
 Low platelets

TREATMENT
 Platelets 1 adult dose




RESULTS
 EXTEM CT ≥ 90s
 AND
 FIBTEM A5 > 10 mm

DIAGNOSIS
 Low coagulation
 factors

TREATMENT
 FFP 2-4 units
 OR
 PCC 10 Units/kg

30 min (Check)



RESULTS
 EXTEM ML ≥ 15%

DIAGNOSIS
 Hyperfibrinolysis

TREATMENT
 Tranexamic Acid 1g IV

Summary


- > What is it...?
- > Do I need it?
- > How do I get it?
- > What else do I need?
- > Prove its easy to interpret.....
 - +/- cases (time..!)




Cases




Bleeding post Surgery




Fibrinogen




Bleeding




Platelets





Heparin effect




2015-03-23T13:04:51 | v2.6.1 | User: admin


Temperature: 37.0°C | Pre | 1 | 2 | 3 | 4



Bleeding post-op in ICU



NORMAL ? Surgical Bleeding



Online Cases

- > <https://www.obsgynaecritcare.org/rotem-flip-cards-test-interpretation-skills/>

